The pandemic of infection with the severe acute respiratory syndrome coronavirus (SARS‐CoV‐2) causing the atypical pneumonia coronavirus disease 19 (Covid‐2019) has become a global health emergency. In parallel with the spread of the infection, there are new information on cutaneous involvement reminiscent to autoimmune diseases and concerns about the risk of disease and management of patients with cutaneous autoimmunity under immunosuppression.